Terra CoV-2 vaccine candidate company Oragenics Inc (NYSE American:OGEN) said on Friday that it has priced its underwritten public offering of 14,189,189 shares of its common stock.

Under the public offering, the company issued the shares at a price of USD0.37 per share for gross proceeds from expected gross proceeds of approximately USD5,250,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

The company has provided the underwriters with a 45-day option to purchase up to an additional 2,128,378 shares of common stock to cover over-allotments, if any.

AGP/Alliance Group Partners is acting as sole book-running manager for the offering. The offering is expected to close on or about 24 November 2020, subject to customary closing conditions.

Net proceeds may be used by the company to continue funding our pre-clinical development of its SARS-CoV-2 vaccine, Terra CoV-2 and antibiotics programme, general corporate purposes, research and development activities, capital expenditures as well as working capital.